Phosphodiesterase type 5 inhibitors and erectile dysfunction
Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management of ED. The PDE5-inhibitors have provided an e...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2010-06-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/1581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management of ED. The PDE5-inhibitors have provided an effective and patient-acceptable therapy for ED. They have had a huge impact on public awareness and understanding of this disease. This article provides an overview of erectile dysfunction and the pharmacology, efficacy, safety and optimal use of the PDE5-inhibitors. |
|---|---|
| ISSN: | 2078-6190 2078-6204 |